etodolac has been researched along with Breast Cancer in 4 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with resectable breast cancer planned for initial management with surgical resection were enrolled and took 400 mg of etodolac twice daily prior to surgery." | 6.80 | A window-of-opportunity biomarker study of etodolac in resectable breast cancer. ( Blair, SL; Carson, DA; Crain, B; Kato, S; Messer, K; Parker, BA; Pu, M; Schwab, RB; Wallace, AM; Weidner, N, 2015) |
| " Here, in a phase-II biomarker clinical trial in breast cancer patients (n = 38), we tested the combined perioperative use of the β-blocker, propranolol, and the COX2-inhibitor, etodolac, scheduled for 11 consecutive perioperative days, starting 5 days before surgery." | 5.27 | Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome. ( Allweis, T; Barshack, I; Ben-Eliyahu, S; Birnbaum, Y; Cole, S; Haldar, R; Lavon, H; Lyons, YA; Shaashua, L; Sharon, E; Sood, AK; Zmora, O, 2018) |
| "Patients with resectable breast cancer planned for initial management with surgical resection were enrolled and took 400 mg of etodolac twice daily prior to surgery." | 2.80 | A window-of-opportunity biomarker study of etodolac in resectable breast cancer. ( Blair, SL; Carson, DA; Crain, B; Kato, S; Messer, K; Parker, BA; Pu, M; Schwab, RB; Wallace, AM; Weidner, N, 2015) |
| "Etodolac was used for these experiments, and was found to induce cell death in a time dependent manner over a 2." | 1.32 | MCF-7 breast cancer cell line grown in agarose culture for study of COX-2 inhibitors in three-dimensional growth system. ( Aulthouse, AL; Kinder, DH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haldar, R | 1 |
| Shaashua, L | 1 |
| Lavon, H | 1 |
| Lyons, YA | 1 |
| Zmora, O | 1 |
| Sharon, E | 1 |
| Birnbaum, Y | 1 |
| Allweis, T | 1 |
| Sood, AK | 1 |
| Barshack, I | 1 |
| Cole, S | 1 |
| Ben-Eliyahu, S | 1 |
| Schwab, RB | 1 |
| Kato, S | 1 |
| Crain, B | 1 |
| Pu, M | 1 |
| Messer, K | 1 |
| Weidner, N | 1 |
| Blair, SL | 1 |
| Wallace, AM | 1 |
| Carson, DA | 1 |
| Parker, BA | 1 |
| Roy, D | 1 |
| Arason, GA | 1 |
| Chowdhury, B | 1 |
| Mitra, A | 1 |
| Calaf, GM | 1 |
| Kinder, DH | 1 |
| Aulthouse, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Perioperative Use of a β-adrenergic Blocker, Propranolol, and a COX2 Inhibitor, Etodolac, in Patients Undergoing Resection With Curative Intent for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Survival[NCT03919461] | Phase 2 | 200 participants (Anticipated) | Interventional | 2019-02-28 | Recruiting | ||
| Perioperative Use of a Beta-adrenergic Blocker and a COX-2 Inhibitor in Patients Undergoing Surgery With Primary Pancreatic Cancer: Intervention Aiming to Reduce Pro-metastatic Processes[NCT03838029] | Phase 2 | 210 participants (Anticipated) | Interventional | 2019-11-20 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for etodolac and Breast Cancer
2 other studies available for etodolac and Breast Cancer
| Article | Year |
|---|---|
Profiling of cell cycle genes of breast cells exposed to etodolac.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclooxygenase Inhibitors; Etodolac; Female; Gene Ex | 2010 |
MCF-7 breast cancer cell line grown in agarose culture for study of COX-2 inhibitors in three-dimensional growth system.
Topics: Breast Neoplasms; Cell Culture Techniques; Cell Death; Cell Division; Cell Line, Tumor; Cyclooxygena | 2004 |